Page 3 - Inflarx Commitment Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Inflarx commitment program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Inflarx Commitment Program Today - Breaking & Trending Today

InflaRx: EMA Reviews MAA For Vilobelimab For Critically Ill COVID-19 Patients; Stock Up In Premarket

InflaRx N.V. (IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, Wednesday said the European Medicines Agency or EMA has validated its Marketing Authorization Application or MAA for Vilobelimab to treat Critically Ill COVID-19 Patients. ....

United States , European Medicines Agency , European Committee For Medicinal Products Human , More Such Health News , Drug Administration , European Union , Marketing Authorization Application , Critically Ill , European Committee , Medicinal Products , Human Use , Lancet Respiratory , Biologics License Application , Covid 19 , Nflarx Maa ,

Retail investors who have a significant stake must be disappointed along with institutions after InflaRx N.V.'s (NASDAQ:IFRX) market cap dropped by US$37m

Key Insights InflaRx's significant retail investors ownership suggests that the key decisions are influenced by. ....

Niels Riedemann , Public Company Ownership , Suvretta Capital Management , Retail Investors , Nstitutional Ownership , Nsider Ownership , Institutional Investors ,

InflaRx Reports Second Quarter 2023 Financial Results & Operating Update

10.08.2023 - • Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States • Oral C5aR inhibitor INF904 progressing in single ascending dose (SAD) and multiple ascending . ....

United States , Katja Arnold , Thomas Taapken , Nielsc Riedemann , Laurie Doyle , Camilla Chong , Regina Lutz , Development Of Vilobelimab , European Medicines Agency , Global Medical Affairs Therapy Area Head , Exchange Commission , Drug Administration , Kyowa Kirin Corporation , Inflarx Pharmaceuticals Inc , Development Expenses , Mc Services , Chief Medical , Chief Executive Officer , Chief Medical Officer , Vice President , Global Medical Affairs , Therapy Area Head , Biologics License Application , European Committee , Medicinal Products , Human Use ,

InflaRx (NASDAQ:IFRX) Sees Significant Drop in Short Interest

InflaRx (NASDAQ:IFRX – Get Rating) was the recipient of a significant decrease in short interest during the month of May. As of May 15th, there was short interest totalling 705,400 shares, a decrease of 26.3% from the April 30th total of 956,900 shares. Based on an average daily trading volume, of 2,410,000 shares, the short-interest […] ....

Niels Christoph Riedemann , Nicolas Fulpius , Raymond James , Renfeng Guo , Jpmorgan Chase Co , Kestra Advisory Services , Group One Trading , Virtu Financial , Raymond James Associates , Get Rating , Advisory Services , Inflarx Daily , Nasdaq Ifrx ,

InflaRx N : These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann Arbor, Michigan, United States (together, the "Group"). The financial statements are presented in Euro (€) - Form 6-K

These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena,. | May 11, 2023 ....

United States , Noord Holland , Ann Arbor , Inflarx Gmb , Company Or Inflarx , Articles Of Association The Company , Public Health Emergency , Drug Administration , Netherlands Chamber , Company The Board Of Directors On , Inflarx Pharmaceuticals Inc , Inflarx Gmbh , Condensed Consolidated Statements , Comprehensive Loss , Financial Position , Shareholder Equity , Cash Flows , Commercial Register , Commerce Business Register , Winzerlaer Stra , Nasdaq Global Select Market , Inflarx Pharmaceuticals , Accounting Estimates , Single Transaction , Accounting Policies , Financial Statements ,